All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
On June 1, 2023, the U.S. Food and Drug Administration (FDA) lifted the clinical hold on the phase I dose escalation study of FHD-286, a highly potent, selective, allosteric, orally available inhibitor of BRG1 (SMARCA4) and BRM (SMARCA2) for the treatment of patients with relapsed and/or refractory (R/R) acute myeloid leukemia (AML) (NCT04891757).1
Following initiation of a partial clinical hold on May 19, 2022,2 the FDA then placed a full clinical hold on the phase I study on August 23, 2022, due to suspected cases of fatal differentiation syndrome.3 In response to the clinical hold, an independent adjudication committee of leading AML experts determined that the rate of differentiation syndrome was 15%, with one case considered definitive for differentiation syndrome but not contributing to the patient’s death.1
The clinical hold has been lifted following protocol amendments and plans to initiate a phase I study of FHD-286 in combination with decitabine or low-dose cytarabine in patients with R/R AML.1 Decitabine and cytarabine are cytoreductive and may reduce the risk of differentiation syndrome. This phase I combination study, to assess the safety, tolerability, and efficacy of FHD-286 in R/R AML, is expected to begin later in 2023; patients will receive a dose escalation of FHD-286 with fixed-dose decitabine or fixed-dose cytarabine in a 3+3 dose escalation design.1
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox